Table of Content

1. Research Methodology


2. Introduction to Transdermal Patch
2.1 Classification of Transdermal Patches
2.2 Why There Exist Need for Transdermal Patches?
2.3 Mechanism of Transdermal Patch Drug Delivery


3. US Transdermal Patch Market Overview
3.1 Current Market Scenario
3.2 Patch Market Opportunity Assessment By Indication
3.2.1 Parkinson’s Disease
3.2.2 Alzheimer’s Disease
3.2.3 Female Contraceptive
3.2.4 Nicotine Replacement Therapy
3.2.5 Cardiovascular Disease
3.2.6 Insulin
3.2.7 Vaccine
3.3 US Transdermal Patch Market Future Trends


4. US Transdermal Patch Clinical Pipeline Overview
4.1 By Company
4.2 By Drug Class
4.3 By Indication
4.4 By Phase


5. Cardiovascular Diseases Transdermal Patch - US Market Availability, Dosage & Price Analysis
5.1 Clonidine Transdermal Patch (Catapres–TTS)
5.2 Nitroglycerin Transdermal Patch


6. Opioid Drug Containing Transdermal Patches - US Market Availability, Dosage & Price Analysis
6.1 Fentanyl Transdermal Patch (Duragesic)
6.2 Buprenorphine Transdermal Patch (Butrans Patch)


7. Neurological Disorders Transdermal Patch - US Market Availability, Dosage & Price Analysis
7.1 Selegiline Transdermal Patch (Emsam)
7.2 Scopolamine Transdermal Patch (Transderm-Scop)
7.3 Rivastigmine Transdermal Patch (Exelon)
7.4 Methylphenidate Transdermal Patch (Daytrana)
7.5 Asenapine Transdermal Patch (Secuado)
7.6 Rotigotine Transdermal Patch (Neupro)
7.7 Donepezil Transdermal Patch (Adlarity)
7.8 Dextroamphetamine Transdermal Patch (Xelstrym)


8. Hormonal Therapy Transdermal Patch - US Market Availability, Dosage & Price Analysis
8.1 Estradiol Transdermal Patch
8.2 Testosterone Transdermal Patch (Androderm)
8.3 Ethinyl Estradiol & Norelgestromin Transdermal Patch
8.4 Estradiol/Levonorgestrel Transdermal Patch (Climara Pro)
8.5 Ethinyl Estradiol/Levonorgestrel (Twirla)


9. Transdermal Patches for Other Conditions - US Market Availability, Dosage & Price Analysis
9.1 Nicotine Transdermal Patch (Nicoderm CQ/Harbitrol)
9.2 Oxybutynin Transdermal Patch (Oxytrol)
9.3 Sancuso (Granisetron)


10. US Transdermal Patch Clinical Pipeline By Company, Indication and Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III
10.7 Preregistration
10.8 Registered


11. US Marketed Transdermal Patch Clinical Insight by Company & Indication


12. US Transdermal Patch Market Dynamics
12.1 Favorable Market Parameters
12.2 Commercialization Challenges


13. Competitive Landscape
13.1 AbbVie
13.2 Amneal Pharmaceuticals
13.3 Cumberland Pharmaceuticals
13.4 Glaxosmithkline
13.5 Hisamitsu Pharmaceutical
13.6 Lavipharm S.A.
13.7 Luye Pharma Group
13.8 Novartis
13.9 Nutriband
13.10 Pfizer
13.11 UCB
13.12 Viatris



List of Tables

Table 2-1: Differences between Active & Passive Transdermal Patches
Table 2-2: Transdermal Patches for Various Disease Indications

Table 3-1: Features Required in Transdermal Patches
Table 3-2: US - Different Transdermal Drug Delivery Systems Available in Market
Table 3-3: US - Estimated Adoption Rates for Parkinson’s Disease Transdermal Patches, 2021-2028
Table 3-4: Description of Neupro Patch for Parkinson’s Disease
Table 3-5: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer’s Disease, 2021-2028
Table 3-6: Transdermal Patches for Alzheimer’s Disease
Table 3-7: Description of Ortho Evra Contraceptive Patch
Table 3-8: Difference Between Generic & Branded Transdermal Contraceptive Products
Table 3-9: US - Estimated Adoption Rates for Nicotine Transdermal Patches, 2022-2028
Table 3-10: Clonidine Patch - Difference Between Generic & Branded Transdermal Patch
Table 3-11: US - Estimated Adoption Rates for Hypertension Transdermal Patches, 2021-2028
Table 3-12: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2021-2028
Table 3-13: US - Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2021-2028

Table 6-1: Duragesic - Initial Dose Conversion from Other Opioids
Table 6-2: Butrans – Initial Dose Calculation using Previous Opioid (Morphine) Dosage

Table 7-1: Daytrana - Dose Increment Pattern for Treatment of ADHD